Loading asset research
Savara Inc. Common Stock
SVRANasdaq · USD · StocksQuote as of · Exchange session not verified$5.30
-0.28%
Today
SVRA
Loading 1D prices…
Market cap
$1.1B
Volume
1.1M
52w high
$7.0152w low
$3.34Company profile
Savara Inc. Common Stock
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Yardley, Pennsylvania.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
Yardley, PA, United States
Employees
70
Fiscal year end
1231
CIK
1160308
Session & valuation
Open$5.38
Previous close$5.32
Day high$5.39
Day low$5.27
30-day avg. volume1.5M
Outstanding shares205.5M
Diluted EPS-$0.53
Latest annual period
P/E (trailing)-10.01
P/E (forward)-16.99
Price / book7.64
Beta0.25
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2834
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| CRVSCorvus Pharmaceuticals Inc. Common Stock | $1.1B | $0.00 | — | -$0.53 | -0.23% | Buy |
| APMDApnimed Inc. Common Stock | $1.1B | $38.5M | -2.42% | -$0.03 | -1.79% | Buy |
| OBXObsidian Therapeutics Inc. Common Stock | $1.1B | $0.00 | — | -$1.63 | +4.72% | Buy |
| MLTXMoonLake Immunotherapeutics Class A Ordinary Shares | $1.1B | $0.00 | — | -$3.53 | -5.14% | Buy |
| JANXJanux Therapeutics Inc. Common Stock | $1B | $10M | -1136.25% | -$1.83 | -3.39% | Buy |